866-997-4948(US-Canada Toll Free)

Neurological Biomarkers Market: Product Diversification Remains Key Strategy for Key Manufactures: Global Industry Analysis (2012 - 2016) and Forecast (2017 - 2025)

Published By :

Future Market Insights

Published Date : Apr 2018

Category :

Pharmaceutical

No. of Pages : 259 Pages

Genomics emerges as the trending biomarker type, and is expected to witness impressive growth

Neurology disorders are affecting major percentage of the global population and it is considered a major cause of disability around the globe. The prevalence of neurological disorders is growing at a very high pace, in which biomarkers are expected play a vital role in better understanding of the disease and development of personalized medicine specific to the patient. There are different types of biomarkers in the market, such as Genomics Biomarker, Proteomics Biomarker, Metabolomics Biomarkers, Imaging Biomarkers, Others. Among these, geonomics biomarker is expected to hold a higher market value reach over US$ 2,700 Mn by the end of 2025.

With the advancements taking place in the healthcare industry and expansion of neurological biomarkers market, new trends are being introduced in the market. A latest trend introduces genomics to the biomarkers market. The process is considered to be an efficient process of examining a disease at the genetic level. It can play major role in the drug development and personalized medicine too. Imaging biomarkers has also come up as one attractive biomarker type, which is expected to witness growth at a high rate in the years coming ahead. Metabolomics biomarkers is also one of these attractive category in the market which is expected to be a lucrative segment in the coming years.

Neurological biomarkers market stands strong in terms of business, as the market demands personalized medicines

Early diagnosis of neurological diseases plays a crucial role in successful management of the disease. Neurological system has limited accessibility and thus, makes diagnosis of the disease a difficult process. Moreover, presently available diagnostic procedures lack sensitivity and specificity for evaluation of disease progression and prognosis. Neurological disorders are diagnosed with cognitive testing, clinical history, structural MRI and neurological examination. However, there are few circumstances wherein identification of specific biomarker is required to understand the diagnosis and treatment of the disease. Biomarker is considered as an indicator in evaluation and measurement of a pathological and physiological process or indicator for pharmacological response to a treatment. Biomarkers are common reference point for diagnosis of disease and play a major role in the development of personalized medicine. There has been significant progress in understanding of onset and development of neurological diseases at the epigenomic and genomic levels. It leads to rapid development of biomarkers in diagnosis of disease with main emphasis in personalized medicine. The growth is expected to take place rapidly, with the requirements of personalized medicines in the coming years.

The market is expected to be stay active also with the increase in research initiatives taking place. There is a huge demand for identifying and validating biomarkers from a large number of population and conducting the research process with the help of this method. It is anticipated to be major factor marking the growth of neurological biomarkers market.

Heterogeneity of Disease turns out to be a stout hindrance in the growth of neurological biomarkers market

In case of heterogeneity, the same disease phenotype is produced with multiple interrelated processes and it increases the difficulty of discovery of biomarkers in degenerative diseases. Such cases can be misleading and increases the complications of the detection and analysis process. It leads to confusion between abnormal and normal health conditions. The clinical symptoms of one disease may be identified by number of heterogeneous Omics variations. Such cases can tone down the expectations of people from neurological biomarkers process and also hamper the growth of its market globally.
1. Executive Summary

A gist of the report, highlighting the key takeaways

1.1. Market Overview

1.2. Market Analysis

1.3. PMR Analysis and Recommendations

1.4. Wheel of Fortune

2. Market Introduction

A definition of Neurological Biomarkers and related market taxonomy

2.1. Market Definition

2.2. Market Taxonomy

2.3. Neurological Biomarkers Market Overview

2.4. Company and Chief Analyst Credentials

3. Market View Point

Tracking the market scenario, with key inferences drawn from historical data, current trends, and future prospects

3.1. Macro-Economic Factors

3.2. Opportunity Analysis

4. Market Background

4.1. Technology Evolution and List of Neurological Biomarkers

4.2. List of Growth Hacking Manufacturers

5. Industry Structure

5.1. Marketing and Distribution Strategies

5.2. Market Size by Tiers

6. Macroeconomic Assumptions

7. Global Economic Outlook

7.1. Gross Domestic Product by Region & Country, 2006 2021

7.2. Disease Outlook

8. North America Neurological Biomarkers Market Analysis 20122016 and Forecast 20172025

Market forecast and analysis in the U.S. and Canada

8.1. Introduction

8.2. Key Regulations

8.3. Regional Market Dynamics

8.3.1. Drivers

8.3.2. Restraints

8.3.3. Trends

8.4. Historical Market Size (US$ Mn) Analysis By Country, 20122016

8.4.1. U.S.

8.4.2. Canada

8.5. Market Size (US$ Mn) Forecast By Country, 20172025

8.5.1. U.S.

8.5.2. Canada

8.6. Historical Market Size (US$ Mn) Analysis By Type, 20122016

8.6.1. Genomics Biomarker

8.6.2. Proteomic Biomarker

8.6.3. Metabolomics Biomarker

8.6.4. Imaging biomarkers

8.6.5. Others

8.7. Market Size (US$ Mn) Forecast By Type, 20172025

8.7.1. Genomics Biomarker

8.7.2. Proteomic Biomarker

8.7.3. Metabolomics Biomarker

8.7.4. Imaging biomarkers

8.7.5. Others

8.8. Historical Market Size (US$ Mn) Analysis By Application, 2012-2016

8.8.1. Alzheimers disease

8.8.2. Parkinsons disease

8.8.3. Huntingtons disease

8.8.4. Schizophrenia

8.8.5. Depression

8.8.6. Multiple Sclerosis

8.8.7. Spinal Muscular Atrophy (SMA)

8.9. Market Size (US$ Mn) Forecast By Application, 2017-2025

8.9.1. Alzheimers disease

8.9.2. Parkinsons disease

8.9.3. Huntingtons disease

8.9.4. Schizophrenia

8.9.5. Depression

8.9.6. Multiple Sclerosis

8.9.7. Spinal Muscular Atrophy (SMA)

8.10. Historical Market Size (US$ Mn) Analysis By End User, 2012-2016

8.10.1. Research Institutes and Diagnostic Centers

8.10.2. Hospitals

8.11. Market Size (US$ Mn) Forecast By End User, 2017-2025

8.11.1. Research Institutes and Diagnostic Centers

8.11.2. Hospitals

8.12. Market Attractiveness Analysis

8.12.1. By Country

8.12.2. By Type

8.12.3. By Application

8.12.4. By End User

8.13. Key Representative Market Participants

8.14. Key Participants Market Presence (Intensity Map)

9. Latin America Neurological Biomarkers Market Analysis 20122016 and Forecast 20172025

Market forecast and analysis in Brazil, Mexico, Argentina and Rest of Latin America

9.1. Introduction

9.2. Key Regulations

9.3. Regional Market Dynamics

9.3.1. Drivers

9.3.2. Restraints

9.3.3. Trends

9.4. Historical Market Size (US$ Mn) Analysis By Country, 20122016

9.4.1. Brazil

9.4.2. Mexico

9.4.3. Argentina

9.4.4. Rest of Latin America

9.5. Market Size (US$ Mn) Forecast By Country, 20172025

9.5.1. Brazil

9.5.2. Mexico

9.5.3. Argentina

9.5.4. Rest of Latin America

9.6. Historical Market Size (US$ Mn) Analysis By Type, 20122016

9.6.1. Genomics Biomarker

9.6.2. Proteomic Biomarker

9.6.3. Metabolomics Biomarker

9.6.4. Imaging biomarkers

9.6.5. Others

9.7. Market Size (US$ Mn) Forecast By Type, 20172025

9.7.1. Genomics Biomarker

9.7.2. Proteomic Biomarker

9.7.3. Metabolomics Biomarker

9.7.4. Imaging biomarkers

9.7.5. Others

9.8. Historical Market Size (US$ Mn) Analysis By Application, 2012-2016

9.8.1. Alzheimers disease

9.8.2. Parkinsons disease

9.8.3. Huntingtons disease

9.8.4. Schizophrenia

9.8.5. Depression

9.8.6. Multiple Sclerosis

9.8.7. Spinal Muscular Atrophy (SMA)

9.9. Market Size (US$ Mn) Forecast By Application, 2017-2025

9.9.1. Alzheimers disease

9.9.2. Parkinsons disease

9.9.3. Huntingtons disease

9.9.4. Schizophrenia

9.9.5. Depression

9.9.6. Multiple Sclerosis

9.9.7. Spinal Muscular Atrophy (SMA)

9.10. Historical Market Size (US$ Mn) Analysis By End User, 2012-2016

9.10.1. Research Institutes and Diagnostic Centers

9.10.2. Hospitals

9.11. Market Size (US$ Mn) Forecast By End User, 2017-2025

9.11.1. Research Institutes and Diagnostic Centers

9.11.2. Hospitals

9.12. Market Attractiveness Analysis

9.12.1. By Country

9.12.2. By Type

9.12.3. By Application

9.12.4. By End User

9.13. Key Representative Market Participants

9.14. Key Participants Market Presence (Intensity Map)

10. Europe Neurological Biomarkers Market Analysis 20122016 and Forecast 20172025

Market forecast and analysis in Germany, France, Italy, Spain, U.K., Russia, and rest of Europe

10.1. Introduction

10.2. Key Regulations

10.3. Regional Market Dynamics

10.3.1. Drivers

10.3.2. Restraints

10.3.3. Trends

10.4. Historical Market Size (US$ Mn) Analysis By Country, 20122016

10.4.1. Germany

10.4.2. France

10.4.3. U.K.

10.4.4. Spain

10.4.5. Italy

10.4.6. Russia

10.4.7. Rest of Europe

10.5. Market Size (US$ Mn) Forecast By Country, 20172025

10.5.1. Germany

10.5.2. France

10.5.3. U.K.

10.5.4. Spain

10.5.5. Italy

10.5.6. Russia

10.5.7. Rest of Europe

10.6. Historical Market Size (US$ Mn) Analysis By Type, 20122016

10.6.1. Genomics Biomarker

10.6.2. Proteomic Biomarker

10.6.3. Metabolomics Biomarker

10.6.4. Imaging biomarkers

10.6.5. Others

10.7. Market Size (US$ Mn) Forecast By Type, 20172025

10.7.1. Genomics Biomarker

10.7.2. Proteomic Biomarker

10.7.3. Metabolomics Biomarker

10.7.4. Imaging biomarkers

10.7.5. Others

10.8. Historical Market Size (US$ Mn) Analysis By Application, 2012-2016

10.8.1. Alzheimers disease

10.8.2. Parkinsons disease

10.8.3. Huntingtons disease

10.8.4. Schizophrenia

10.8.5. Depression

10.8.6. Multiple Sclerosis

10.8.7. Spinal Muscular Atrophy (SMA)

10.9. Market Size (US$ Mn) Forecast By Application, 2017-2025

10.9.1. Alzheimers disease

10.9.2. Parkinsons disease

10.9.3. Huntingtons disease

10.9.4. Schizophrenia

10.9.5. Depression

10.9.6. Multiple Sclerosis

10.9.7. Spinal Muscular Atrophy (SMA)

10.10. Historical Market Size (US$ Mn) Analysis By End User, 2012-2016

10.10.1. Research Institutes and Diagnostic Centers

10.10.2. Hospitals

10.11. Market Size (US$ Mn) Forecast By End User, 2017-2025

10.11.1. Research Institutes and Diagnostic Centers

10.11.2. Hospitals

10.12. Market Attractiveness Analysis

10.12.1. By Country

10.12.2. By Type

10.12.3. By Application

10.12.4. By End User

10.13. Key Representative Market Participants

10.14. Key Participants Market Presence (Intensity Map)

11. Asia Pacific Neurological Biomarkers Market Analysis 20122016 and Forecast 20172025

Market forecast and analysis in China, India, Japan, ASEAN, Australia & New Zealand, and Rest of Asia Pacific

11.1. Introduction

11.2. Key Regulations

11.3. Regional Market Dynamics

11.3.1. Drivers

11.3.2. Restraints

11.3.3. Trends

11.4. Historical Market Size (US$ Mn) Analysis By Country, 20122016

11.4.1. China

11.4.2. India

11.4.3. Japan

11.4.4. Australia and New Zealand

11.4.5. ASEAN

11.4.6. Rest of Asia Pacific

11.5. Market Size (US$ Mn) Forecast By Country, 20172025

11.5.1. China

11.5.2. India

11.5.3. Japan

11.5.4. Australia and New Zealand

11.5.5. ASEAN

11.5.6. Rest of Asia Pacific

11.6. Historical Market Size (US$ Mn) Analysis By Type, 20122016

11.6.1. Genomics Biomarker

11.6.2. Proteomic Biomarker

11.6.3. Metabolomics Biomarker

11.6.4. Imaging biomarkers

11.6.5. Others

11.7. Market Size (US$ Mn) Forecast By Type, 20172025

11.7.1. Genomics Biomarker

11.7.2. Proteomic Biomarker

11.7.3. Metabolomics Biomarker

11.7.4. Imaging biomarkers

11.7.5. Others

11.8. Historical Market Size (US$ Mn) Analysis By Application, 2012-2016

11.8.1. Alzheimers disease

11.8.2. Parkinsons disease

11.8.3. Huntingtons disease

11.8.4. Schizophrenia

11.8.5. Depression

11.8.6. Multiple Sclerosis

11.8.7. Spinal Muscular Atrophy (SMA)

11.9. Market Size (US$ Mn) Forecast By Application, 2017-2025

11.9.1. Alzheimers disease

11.9.2. Parkinsons disease

11.9.3. Huntingtons disease

11.9.4. Schizophrenia

11.9.5. Depression

11.9.6. Multiple Sclerosis

11.9.7. Spinal Muscular Atrophy (SMA)

11.10. Historical Market Size (US$ Mn) Analysis By End User, 2012-2016

11.10.1. Research Institutes and Diagnostic Centers

11.10.2. Hospitals

11.11. Market Size (US$ Mn) Forecast By End User, 2017-2025

11.11.1. Research Institutes and Diagnostic Centers

11.11.2. Hospitals

11.12. Market Attractiveness Analysis

11.12.1. By Country

11.12.2. By Type

11.12.3. By Application

11.12.4. By End User

11.13. Key Representative Market Participants

11.14. Key Participants Market Presence (Intensity Map)

12. MEA Neurological Biomarkers Market Analysis 20122016 and Forecast 20172025

Market forecast and analysis in GCC, South Africa, and Rest of MEA

12.1. Introduction

12.2. Key Regulations

12.3. Regional Market Dynamics

12.3.1. Drivers

12.3.2. Restraints

12.3.3. Trends

12.4. Historical Market Size (US$ Mn) Analysis By Country, 20122016

12.4.1. GCC Countries

12.4.2. South Africa

12.4.3. Rest of MEA

12.5. Market Size (US$ Mn) Forecast By Country, , 20172025

12.5.1. GCC Countries

12.5.2. South Africa

12.5.3. Rest of MEA

12.6. Historical Market Size (US$ Mn) Analysis By Type, 20122016

12.6.1. Genomics Biomarker

12.6.2. Proteomic Biomarker

12.6.3. Metabolomics Biomarker

12.6.4. Imaging biomarkers

12.6.5. Others

12.7. Market Size (US$ Mn) Forecast By Type, 20172025

12.7.1. Genomics Biomarker

12.7.2. Proteomic Biomarker

12.7.3. Metabolomics Biomarker

12.7.4. Imaging biomarkers

12.7.5. Others

12.8. Historical Market Size (US$ Mn) Analysis By Application, 2012-2016

12.8.1. Alzheimers disease

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title
  • Company
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *